Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma

出版年份 2019 全文链接

标题

作者

关键词

binimetinib; MEK inhibitor; biomarker; melanoma; phase II

出版物

Volume 10, Issue 19, Pages -

出版商

Impact Journals, LLC

发表日期

2019-03-05

DOI

10.18632/oncotarget.26753

联系作者

Discuss science. Find collaborators. Network.

Join a conversation

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now